|
EP0889876B1
(en)
*
|
1996-03-29 |
2001-07-25 |
G.D. SEARLE & CO. |
Meta-substituted phenylene sulphonamide derivatives
|
|
GB9805655D0
(en)
|
1998-03-16 |
1998-05-13 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6521626B1
(en)
|
1998-03-24 |
2003-02-18 |
Celltech R&D Limited |
Thiocarboxamide derivatives
|
|
NZ507222A
(en)
|
1998-04-09 |
2003-05-30 |
Meiji Seika Kaisha |
Aminopiperidine derivatives useful as integrin antagonists
|
|
GB9814414D0
(en)
|
1998-07-03 |
1998-09-02 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
WO2000006169A1
(en)
*
|
1998-07-29 |
2000-02-10 |
Merck & Co., Inc. |
Integrin receptor antagonists
|
|
GB9821061D0
(en)
|
1998-09-28 |
1998-11-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9826174D0
(en)
|
1998-11-30 |
1999-01-20 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
CA2356929A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia
|
|
US6291503B1
(en)
|
1999-01-15 |
2001-09-18 |
Bayer Aktiengesellschaft |
β-phenylalanine derivatives as integrin antagonists
|
|
US6518283B1
(en)
|
1999-05-28 |
2003-02-11 |
Celltech R&D Limited |
Squaric acid derivatives
|
|
AU6316900A
(en)
|
1999-08-05 |
2001-03-05 |
Meiji Seika Kaisha Ltd. |
Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
|
|
MXPA02002578A
(es)
*
|
1999-09-08 |
2002-10-23 |
Guilford Pharm Inc |
Compuestos de union a ciclofilina no peptidicos, y su uso.
|
|
EP1088821A1
(en)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmaceutically active sulfonamide derivatives
|
|
US6534513B1
(en)
|
1999-09-29 |
2003-03-18 |
Celltech R&D Limited |
Phenylalkanoic acid derivatives
|
|
US20050059669A1
(en)
*
|
1999-10-08 |
2005-03-17 |
Keiichi Ajito |
M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity
|
|
AU781747B2
(en)
*
|
1999-10-08 |
2005-06-09 |
Meiji Seika Kaisha Ltd. |
3-aminopiperidine derivatives as integrin alphavbeta3 antagonists
|
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
|
US6455539B2
(en)
|
1999-12-23 |
2002-09-24 |
Celltech R&D Limited |
Squaric acid derivates
|
|
WO2001056607A1
(en)
*
|
2000-02-03 |
2001-08-09 |
Eisai Co., Ltd. |
Integrin expression inhibitors
|
|
DE60130910T2
(de)
|
2000-04-17 |
2008-07-10 |
Ucb Pharma, S.A. |
Enamin-derivate als zell-adhäsionsmoleküle
|
|
US6403608B1
(en)
|
2000-05-30 |
2002-06-11 |
Celltech R&D, Ltd. |
3-Substituted isoquinolin-1-yl derivatives
|
|
US6545013B2
(en)
|
2000-05-30 |
2003-04-08 |
Celltech R&D Limited |
2,7-naphthyridine derivatives
|
|
US6740654B2
(en)
|
2000-07-07 |
2004-05-25 |
Celltech R & D Limited |
Squaric acid derivatives
|
|
AU2001275724A1
(en)
|
2000-08-02 |
2002-02-13 |
Celltech R&D Limited |
3-substituted isoquinolin-1-yl derivatives
|
|
EP1360173A2
(en)
|
2001-01-25 |
2003-11-12 |
Guilford Pharmaceuticals Inc. |
Trisubstituted carbocyclic cyclophilin binding compounds and their use
|
|
US7122318B2
(en)
*
|
2001-02-21 |
2006-10-17 |
Eisai Co., Ltd. |
Method for testing effect of angiogenesis inhibitor via integrin expression inhibition
|
|
US6710061B2
(en)
*
|
2001-03-09 |
2004-03-23 |
Ortho-Mcneil Pharamceutical, Inc. |
Aminopyrrolidine sulfonamides as serine protease inhibitors
|
|
GB0127615D0
(en)
*
|
2001-07-09 |
2002-01-09 |
Aventis Pharm Prod Inc |
Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
|
|
KR20040058229A
(ko)
|
2001-10-22 |
2004-07-03 |
더 스크립스 리서치 인스티튜트 |
항체 표적화 화합물
|
|
AU2002364260A1
(en)
*
|
2001-12-31 |
2003-07-30 |
Bayer Pharmaceuticals Corporation |
Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins
|
|
JP2005533001A
(ja)
*
|
2002-03-04 |
2005-11-04 |
メディミューン，インコーポレーテッド |
インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
|
|
EP1487489A4
(en)
*
|
2002-03-04 |
2008-10-01 |
Medimmune Inc |
METHOD FOR PREVENTING OR TREATING ILLNESSES BY ADMINISTERING AN INTEGRIN AVB3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
|
|
JP2006516635A
(ja)
*
|
2003-01-30 |
2006-07-06 |
メディミューン，インコーポレーテッド |
インテグリンαｖβ３アンタゴニストの使用
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
US9296697B2
(en)
|
2005-08-24 |
2016-03-29 |
Abbott Laboratories |
Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
|
|
US20070122408A1
(en)
*
|
2005-10-20 |
2007-05-31 |
The Scripps Research Institute |
Fc Labeling for Immunostaining and Immunotargeting
|
|
PT2222636E
(pt)
|
2007-12-21 |
2013-07-16 |
Ligand Pharm Inc |
Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
|
|
US8518927B2
(en)
|
2009-02-10 |
2013-08-27 |
The Scripps Research Institute |
Chemically programmed vaccination
|
|
ES2864079T3
(es)
|
2014-05-30 |
2021-10-13 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
|
|
MX2021012690A
(es)
|
2019-04-19 |
2022-01-31 |
Ligand Pharm Inc |
Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
|
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|